Reality Pharma India Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-12-2024
- Paid Up Capital ₹ 4.75 M
as on 26-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -39.83%
(FY 2022)
- Profit -77.61%
(FY 2022)
- Ebitda -79.68%
(FY 2022)
- Net Worth -207.47%
(FY 2022)
- Total Assets -13.43%
(FY 2022)
About Reality Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.75 M, as per Ministry of Corporate Affairs (MCA) records.
Neeraj Sandil and Dheeraj Kumar serve as directors at the Company.
- CIN/LLPIN
U74999BR2016PTC031945
- Company No.
031945
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Reality Pharma India Private Limited offer?
Reality Pharma India Private Limited offers a wide range of products and services, including Animal Feed Supplement, Cattle Feed Additives, Cattle Vitamins, Veterinary Medicines, Veterinary Bolus, Poultry Feed Supplements, Bird Food, Poultry & Animal Food, Animal Nutraceuticals, Animal Uterine Tonic, Mineral Mixture.
Who are the key members and board of directors at Reality Pharma India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeraj Sandil  | Director | 05-Jul-2016 | Current |
| Dheeraj Kumar | Director | 29-Aug-2021 | Current |
Financial Performance of Reality Pharma India.
Reality Pharma India Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 39.83% decrease. The company also saw a substantial fall in profitability, with a 77.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 207.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reality Pharma India?
In 2022, Reality Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Reality Pharma India?
Reality Pharma India has a workforce of 10 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reality Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reality Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
